Medicações Alfa-2 agonistas adrenérgicos na Unidade de Terapia Intensiva pediátrica: revisão de literatura
DOI:
https://doi.org/10.53660/1510.prw3031Palavras-chave:
Alfa-2 agonistas, Terapia Intensiva Pediátrica, Clonidina, DexmedetomidinaResumo
Os alfa-2 agonistas adrenérgicos são medicações inicialmente utilizadas para controle de pressão arterial. Nos últimos anos foram observados um número cada vez maior de aplicações, principalmente nos campos da Terapia Intensiva e Anestesia. Esse estudo de revisão de literatura, do tipo descritivo, qualitativo, de pesquisa bibliográfica, teve como objetivo revisar as medicações alfa-2 agonistas e sumarizar seus principais usos da Unidade de Terapia Intensiva Pediátrica. A literatura demonstra que as medicações agonistas alfa-2 adrenérgicas, representadas principalmente pela clonidina e dexmedetomidina são consideradas drogas seguras, por não deprimir o centro respiratório enquanto promovem sedação e com menor potencial de instabilidade hemodinâmica. Na pediatria essa segurança e os demais benefícios dos alfa-2 agonistas, não só sedação, como controle de dor, necessidade de uso de menor quantidade de opióides e agentes anestésicos, menor tempo de ventilação mecânica e controle de abstinência medicamentosa têm aberto espaço para um uso cada vez mais frequente dessas medicações.
Downloads
Referências
BAE, Hong-Beom. Dexmedetomidine: an attractive adjunct to anesthesia. Korean Journal Of Anesthesiology, [S.L.], v. 70, n. 4, p. 375-376, 2017. The Korean Society of Anesthesiologists. http://dx.doi.org/10.4097/kjae.2017.70.4.375.
BASKER, Sujatha; SINGH, Georgene; JACOB, Rebecca. Clonidine In Paediatrics – A Review. Indian Journal Of Anaesthesia. Vellore, p. 270-280. abr. 2009.
CHEN, Ken; LU, Zhijun; XIN, Yi Chun; CAI, Yong; CHEN, Yi; PAN, Shu Ming. Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. Cochrane Database Of Systematic Reviews, [S.L.], v. 2019, n. 1, p. 1-80, 6 jan. 2015. Wiley. http://dx.doi.org/10.1002/14651858.cd010269.pub2.
GRANT, Mary Jo C.; SCHNEIDER, James B.; ASARO, Lisa A.; DODSON, Brenda L.; HALL, Brent A.; SIMONE, Shari L.; COWL, Allison S.; MUNKWITZ, Michele M.; WYPIJ, David; CURLEY, Martha A. Q.. Dexmedetomidine Use in Critically Ill Children With Acute Respiratory Failure*. Pediatric Critical Care Medicine, [S.L.], v. 17, n. 12, p. 1131-1141, dez. 2016. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1097/pcc.0000000000000941. Disponível em: https://pubmed.ncbi.nlm.nih.gov/27654816/. Acesso em: 6 set. 2023.
HAYDEN, John C; DAWKINS, Ian; BREATNACH, Cormac; LEACY, Finbarr P; FOXTON, June; HEALY, Martina; COUSINS, Gráinne; GALLAGHER, Paul J; DOHERTY, Dermot R. Effectiveness of α 2 agonists for sedation in paediatric critical care: study protocol for a retrospective cohort observational study. Bmj Open, [S.L.], v. 7, n. 5, p. 1-10, maio 2017. BMJ. http://dx.doi.org/10.1136/bmjopen-2016-013858. Disponível em: http://bmjopen.bmj.com/. Acesso em: 6 set. 2023.
KEOGH, S. J.; LONG, D. A.; HORN, D. V.. Practice guidelines for sedation and analgesia management of critically ill children: a pilot study evaluating guideline impact and feasibility in the picu. Bmj Open, [S.L.], v. 5, n. 3, p. 006428-006428, 30 mar. 2015. BMJ. http://dx.doi.org/10.1136/bmjopen-2014-006428.
LEE, Hyung Gon; CHOI, Jeong Il; KIM, Yeo Ok; YOON, Myung Ha. The role of alpha-2 adrenoceptor subtype in the antiallodynic effect of intraplantar dexmedetomidine in a rat spinal nerve ligation model. Neuroscience Letters, [S.L.], v. 557, p. 118-122, dez. 2013. Elsevier BV. http://dx.doi.org/10.1016/j.neulet.2013.10.002.
MINOURA, Yoshino; ONIMARU, Hiroshi; IIGAYA, Kamon; KOBAYASHI, Youichi. Modulation of sympathetic preganglionic neuron activity via adrenergic receptors. Hypertension Research, [S.L.], v. 41, n. 7, p. 499-505, 10 maio 2018. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/s41440-018-0049-x.
MOGHADDAM, Morteza Jabbary; BARKHORI, Ali; MIRKHESHTI, Alireza; HASHEMIAN, Morteza; MOHAJERANI, Seyed Amir. The Effect of Pre-Emptive Dexmedetomidine on the Incidence of Post-Thoracotomy Pain Syndrome in Patients Undergoing Coronary Artery Bypass Grafting. Anesthesiology And Pain Medicine, [S.L.], v. 6, n. 3, p. 1-6, 6 jun. 2016. Briefland. http://dx.doi.org/10.5812/aapm.36344.
PAN, Wanying; LIN, Lin; ZHANG, Nan; YUAN, Fuli; HUA, Xiaoxiao; WANG, Yueting; MO, Liqiu. Neuroprotective Effects of Dexmedetomidine Against Hypoxia-Induced Nervous System Injury are Related to Inhibition of NF-κB/COX-2 Pathways. Cellular And Molecular Neurobiology, [S.L.], v. 36, n. 7, p. 1179-1188, 18 dez. 2015. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s10571-015-0315-2.
PASICHOW, Keith P.; FRIZZOLA, Meg; MILLER, Elissa G.. Palliative Sedation with Oral Medicines in an Infant with Generalized Severe Junctional Epidermolysis Bullosa. Journal Of Palliative Medicine, [S.L.], v. 21, n. 7, p. 1048-1052, jul. 2018. Mary Ann Liebert Inc. http://dx.doi.org/10.1089/jpm.2018.0054.
READE, Michael C.; EASTWOOD, Glenn M.; BELLOMO, Rinaldo; BAILEY, Michael; BERSTEN, Andrew; CHEUNG, Benjamin; DAVIES, Andrew; DELANEY, Anthony; GHOSH, Angaj; VAN HAREN, Frank. Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium. Jama, [S.L.], v. 315, n. 14, p. 1460-1468, 12 abr. 2016. American Medical Association (AMA). http://dx.doi.org/10.1001/jama.2016.2707.
SCOTT-WARREN, Vl; SEBASTIAN, J. Dexmedetomidine: its use in intensive care medicine and anaesthesia. Bja Education, [S.L.], v. 16, n. 7, p. 242-246, jul. 2016. Elsevier BV. http://dx.doi.org/10.1093/bjaed/mkv047.
TOBIAS, Joseph D.. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatric Critical Care Medicine, [S.L.], v. 8, n. 2, p. 115-131, mar. 2007. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1097/01.pcc.0000257100.31779.41.
WALKER, Tracie; KUDCHADKAR, Sapna R.. Pain and Sedation Management: 2018 update for the rogers⠹ textbook of pediatric intensive care. Pediatric Critical Care Medicine, [S.L.], v. 20, n. 1, p. 54-61, jan. 2019. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1097/pcc.0000000000001765. Disponível em: www.pccmjournal.org. Acesso em: 6 set. 2023.
WANG, Y.; HAN, R.; ZUO, Z.. Dexmedetomidine post-treatment induces neuroprotection via activation of extracellular signal-regulated kinase in rats with subarachnoid haemorrhage. British Journal Of Anaesthesia, [S.L.], v. 116, n. 3, p. 384-392, mar. 2016. Elsevier BV. http://dx.doi.org/10.1093/bja/aev549.
WEERINK, Maud A. S.; STRUYS, Michel M. R. F.; HANNIVOORT, Laura N.; BARENDS, Clemens R. M.; ABSALOM, Anthony R.; COLIN, Pieter. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clinical Pharmacokinetics, [S.L.], v. 56, n. 8, p. 893-913, 19 jan. 2017. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s40262-017-0507-7.